Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B

Diabetes, obesity & metabolism9 Sept 2012Cited by 75 (Europe PMC)

PMID22862847DOI10.1111/j.1463-1326.2012.01673.xPepBankPUB-22862847

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 24.4% lost more than 5% of body weight with liraglutide 1.8 mg, against 9.9% with placebo.
In plain wordsIn adults with type 2 diabetes, more people lost over 5% of body weight with liraglutide 1.8 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion with more than 5% weight loss, liraglutide 1.8 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Proportion with >5% weight loss
24.4%
liraglutide 1.8 mg
Proportion with >5% weight loss
9.9%
placebo
Source sentences
Summary
A number of subjects experienced >5% weight loss during the trials (24.4% liraglutide 1.8 mg and 17.7% liraglutide 1.2 mg; 17.7% exenatide, 10.0% sitagliptin, 3.6-7.0% sulphonylurea, 2.6% thiazolidinedione and 2.6% glargine; 9.9% placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 17.7% lost more than 5% of body weight with liraglutide 1.2 mg, against 9.9% with placebo.
In plain wordsIn adults with type 2 diabetes, more people lost over 5% of body weight with liraglutide 1.2 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion with more than 5% weight loss, liraglutide 1.2 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg · 26 weeksAs given in this study (human).
Measurements
Proportion with >5% weight loss
17.7%
liraglutide 1.2 mg
Proportion with >5% weight loss
9.9%
placebo
Source sentences
Summary
A number of subjects experienced >5% weight loss during the trials (24.4% liraglutide 1.8 mg and 17.7% liraglutide 1.2 mg; 17.7% exenatide, 10.0% sitagliptin, 3.6-7.0% sulphonylurea, 2.6% thiazolidinedione and 2.6% glargine; 9.9% placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 and 1.8 mg gave more weight loss than the active comparators, except exenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide led to more weight loss than most other diabetes drugs tested, but not more than exenatide.
Peptide
Liraglutide
Outcome
IncreaseWeight loss versus active comparators other than exenatide
Study
n: not reported in source
Comparator
Active comparators (excluding exenatide)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 and 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
More weight loss was seen with liraglutide 1.2 and 1.8 mg than with active comparators except exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 and 1.8 mg did not give more weight loss than exenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide did not lead to more weight loss than exenatide.
Peptide
Liraglutide
Outcome
No significant changeWeight loss versus exenatide
Study
n: not reported in source
Comparator
Exenatide
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 and 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
More weight loss was seen with liraglutide 1.2 and 1.8 mg than with active comparators except exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284704
05HumanRandomized controlled trialOther
In adults with type 2 diabetes treated with liraglutide, higher initial BMI was associated with slightly greater weight loss across trials.
In plain wordsIn adults with type 2 diabetes, a higher starting BMI was linked to slightly more weight loss with liraglutide.
Peptide
Liraglutide
Outcome
IncreaseEffect of initial BMI on weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 and 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Across trials, higher initial BMI was associated with slightly greater weight loss with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284705
06HumanRandomized controlled trialOther
In adults with type 2 diabetes, mean weight loss increased slightly the longer gastrointestinal adverse events persisted.
In plain wordsIn adults with type 2 diabetes, weight loss was slightly greater in people whose stomach and gut side effects lasted longer.
Peptide
Liraglutide
Outcome
IncreaseEffect of gastrointestinal adverse event duration on weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 and 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Mean weight loss increased slightly the longer GI AEs persisted.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284706
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide lowered HbA1c beyond what appeared weight-induced, so not all of the effect appears weight mediated.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c by more than weight loss alone seemed to explain.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction beyond weight-induced effect
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 and 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide-treated subjects experienced additional HbA1c reduction beyond that which appeared weight induced; thus, not all HbA1c-lowering effect appears weight mediated.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
Report a problemFND-2286284708

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

08HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes, HbA1c reduction was slightly larger in higher weight loss categories across all treatments, including placebo, but no clear correlation could be determined.
In plain wordsIn adults with type 2 diabetes, no clear link between weight loss and HbA1c lowering could be shown across all treatments, including placebo.
Peptide
Liraglutide
Outcome
No significant changeCorrelation of weight change with HbA1c change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Although HbA1c reduction was slightly larger in higher weight loss categories across treatments (including placebo), sample sizes were small and no clear correlation could be determined.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-six-week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2286284707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials7

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

7 trials · 6 completed · 1 stopped early · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817